Skip to content

In the BioHarmony Drug Report Database

Ketoconazole

Extina, Nizoral, Nizoral Anti-dandruff, Xolegel, Ketoconazole HRA (ketoconazole) is a small molecule pharmaceutical. Ketoconazole was first approved as Extina on 1982-01-01. It is used to treat acanthamoeba keratitis, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, and cutaneous candidiasis amongst others in the USA. It has been approved in Europe to treat cushing syndrome. It is known to target potassium voltage-gated channel subfamily A member 10 and lanosterol 14-alpha demethylase.
Trade Name Ketoconazole HRA
Common Name Ketoconazole
Indication acanthamoeba keratitis, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, cushing syndrome, cutaneous candidiasis, histoplasmosis, leishmaniasis, mycoses, oral candidiasis, paracoccidioidomycosis, seborrheic dermatitis, tinea pedis, tinea versicolor, vulvovaginal candidiasis
Drug Class Systemic antifungals (miconazole type)
Ketoconazole
Get full access now